Aprea Therapeutics Inc (APRE) stock is lower by -77.73% over the last 12 months, and the average rating from Wall Street analysts is a Hold. InvestorsObserver’s proprietary ranking system, gives APRE stock a score of 31 out of a possible 100.
That rank is primarily influenced by a short-term technical score of 0. APRE's rank also includes a long-term technical score of 0. The fundamental score for APRE is 94. In addition to the average rating from Wall Street analysts, APRE stock has a mean target price of 13. This means analysts expect the stock to add 68.61% over the next 12 months.
What's Happening with APRE Stock Today
Aprea Therapeutics Inc (APRE) stock has gained 7.61% while the S&P 500 is lower by -0.1% as of 1:30 PM on Wednesday, Feb 10. APRE has gained $0.55 from the previous closing price of $7.16 on volume of 2,651,421 shares. Over the past year the S&P 500 has gained 16.37% while APRE is lower by -77.73%. APRE lost -$2.30 per share in the over the last 12 months.
Click Here to get the full Stock Score Report on Aprea Therapeutics Inc (APRE) Stock.
